FDA Warns Against Diamond Shruumz Microdosing Chocolates After Severe Illnesses

The U.S. Food and Drug Administration has issued a critical warning regarding a brand of chocolate bars marketed as "microdosing" products, following reports of severe health issues among consumers. At least 12 individuals across eight states have fallen ill after consuming these products, with 10 requiring hospitalization due to symptoms that include seizures, confusion, and abnormal heart rates. The agency's advisory has raised alarms about the safety of these mushroom-infused confections, which are sold under the brand name Diamond Shruumz.

The FDA's investigation began after an initial alert on June 7, when eight cases were reported, primarily from states such as Arizona, Indiana, Nevada, and Pennsylvania. As of June 11, the number of reported cases had risen, prompting the agency to expand its warning to include all flavors of Diamond Shruumz's chocolate bars, gummies, and infused cones. The symptoms experienced by consumers are alarming and include central nervous system depression, agitation, nausea, and vomiting. Fortunately, no fatalities have been reported.

Diamond Shruumz markets its products as containing a "proprietary blend of nootropic and functional mushrooms," claiming to offer a euphoric experience without the psychoactive compound psilocybin, commonly associated with psychedelic mushrooms. However, the lack of transparency regarding the specific ingredients has raised concerns. The company does not provide a detailed ingredient list on its website, and while it promotes its products as safe and natural, the FDA's findings suggest otherwise.

Experts have expressed skepticism about the claims made by Diamond Shruumz. The term "microdosing" typically refers to the practice of consuming sub-perceptual amounts of psychedelic substances to enhance creativity and mood. However, the chocolate bars in question do not contain psilocybin or other scheduled drugs, leading some to question the efficacy and safety of the ingredients used. The FDA has noted that the products are marketed in a way that may appeal to younger consumers, raising additional concerns about their accessibility and potential misuse.

The ongoing investigation involves collaboration between the FDA, the Centers for Disease Control and Prevention, and local poison control centers. Officials are working to determine the exact cause of the illnesses and whether the adverse reactions are linked to the mushroom extracts or other undisclosed ingredients. As the investigation unfolds, the FDA has advised consumers to avoid purchasing or consuming these products and to discard any they may have.

In a statement, the head of Arizona's Poison and Drug Information Center highlighted the seriousness of the situation, noting that the symptoms reported are not typical for foodborne illnesses. "We’ve seen the same phenomenon of people eating the chocolate bar then seizing, losing consciousness, and having to be intubated," he said, indicating that the issue may extend beyond the states currently identified.

The rise of products like Diamond Shruumz reflects a broader trend in the wellness industry, where the use of mushrooms and other natural substances is increasingly marketed for their supposed cognitive and health benefits. However, the lack of regulation in this burgeoning market raises questions about consumer safety and the potential for harmful side effects.

As the FDA continues its investigation, consumers are urged to exercise caution and remain informed about the products they choose to consume. The agency's warning serves as a reminder of the importance of transparency and safety in the food and supplement industries, particularly as interest in alternative health products grows.